{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:16:22Z","timestamp":1788948982165,"version":"build-2803163510"},"reference-count":39,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The phase 1\/2 Intergroup study E4412 investigated checkpoint blockade with nivolumab (Nivo) and ipilimumab (Ipi) combined with the CD30 targeting antibody-drug conjugate brentuximab vedotin (BV) in relapsed\/refractory classic Hodgkin lymphoma. A total of 147 patients aged \u226512 years were randomized between BV\/Nivo and BV\/Ipi\/Nivo; 132 patients were included in the primary efficacy analysis. The complete response (CR) rate, was 64.7% (52.2, 75.9) for BV\/Nivo and 70.3% (57.6, 81.1) for BV\/Ipi\/Nivo (1-sided P = .29). The median survival follow-up was 38.0 months (interquartile range, 32.6-48.1). Progression-free survival (PFS) did not significantly differ between the 2 arms (hazard ratio [HR], 0.78, confidence interval [CI], 0.39-1.57; 1-sided P = .24). Treatment-related grade 3+ toxicities in the adult cohort, excluding rash, were similar between both arms (38.5% BV\/Nivo and 39.3% BV\/Ipi\/Nivo); there was a higher frequency of grade 3 rash with BV\/Ipi\/Nivo (24.6%) compared with BV\/Nivo (9.2%). We compared PFS by stem cell transplantation (SCT) status in a planned before hoc comparison; 58 patients received SCT, and 36-month PFS (from SCT) was &amp;gt;90% for both arms. Sixty-six patients were progression free after the first scan and did not undergo SCT. The 36-month PFS was 73.0% (54.5, 85.0) for BV\/Ipi\/Nivo compared with 45.8% (26.3, 63.4) for BV\/Nivo (HR, 0.45; CI, 0.19-1.08; 1-sided P = .03). The study did not meet its primary end point of superior CR rate for the triplet, but it supports the use of checkpoint antibody-drug conjugate induction prior to auto SCT, and there is an intriguing signal of disease control for patients wishing to defer or avoid SCT with the triplet of BV\/Ipi\/Nivo. This trial was registered at www.clinicaltrials.gov as NCT01896999.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025029546","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T21:10:36Z","timestamp":1770671436000},"page":"2041-2052","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1116-3246","authenticated-orcid":false,"given":"Catherine S.","family":"Diefenbach","sequence":"first","affiliation":[{"name":"1Perlmutter Cancer Center at NYU Langone Health, NYU Grossman School of Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1763-8214","authenticated-orcid":false,"given":"Opeyemi","family":"Jegede","sequence":"additional","affiliation":[{"name":"2Department of Data Science, ECOG-ACRIN Biostatistical Center, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Wang","sequence":"additional","affiliation":[{"name":"2Department of Data Science, ECOG-ACRIN Biostatistical Center, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"3Department of Hematology\/Oncology, Mayo School of Graduate Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5478-8161","authenticated-orcid":false,"given":"Lale","family":"Kostakoglu","sequence":"additional","affiliation":[{"name":"4University of Virginia Cancer Center, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9842-9750","authenticated-orcid":false,"given":"Christian","family":"Steidl","sequence":"additional","affiliation":[{"name":"5Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, Canada"},{"name":"6Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-1018","authenticated-orcid":false,"given":"Yasodha","family":"Natkunam","sequence":"additional","affiliation":[{"name":"7Department of Pathology, Stanford University School of Medicine, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0435-5947","authenticated-orcid":false,"given":"David W.","family":"Scott","sequence":"additional","affiliation":[{"name":"5Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, Canada"},{"name":"8Department of Medicine, The University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4027-3073","authenticated-orcid":false,"given":"Richard F.","family":"Ambinder","sequence":"additional","affiliation":[{"name":"9Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7415-0376","authenticated-orcid":false,"given":"Kevin A.","family":"David","sequence":"additional","affiliation":[{"name":"10Rutgers Cancer Institute, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana H.","family":"Advani","sequence":"additional","affiliation":[{"name":"11Stanford Cancer Institute, Stanford University School of Medicine, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8470-394X","authenticated-orcid":false,"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"12Division of Oncology, Washington University School of Medicine, Saint Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Roberston","sequence":"additional","affiliation":[{"name":"13Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5841-9213","authenticated-orcid":false,"given":"Sachdev P.","family":"Thomas","sequence":"additional","affiliation":[{"name":"14Department of Hematology\/Oncology, Kaiser Permanente-Vallejo, Vallejo, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2723-6481","authenticated-orcid":false,"given":"Jonathon","family":"Cohen","sequence":"additional","affiliation":[{"name":"15Winship Cancer Institute, Emory University, Atlanta CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Ibrahimi","sequence":"additional","affiliation":[{"name":"16Department of Hematology Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6148-5177","authenticated-orcid":false,"given":"Gaurav","family":"Goyal","sequence":"additional","affiliation":[{"name":"17Department of Hematology Oncology, The University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5744-0670","authenticated-orcid":false,"given":"Neha","family":"Mehta-Shah","sequence":"additional","affiliation":[{"name":"12Division of Oncology, Washington University School of Medicine, Saint Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4117-2469","authenticated-orcid":false,"given":"Jennifer E.","family":"Amengual","sequence":"additional","affiliation":[{"name":"18Department of Hematology Oncology, Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Forlenza","sequence":"additional","affiliation":[{"name":"19Department of Pediatric Hematology Oncology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3525-8015","authenticated-orcid":false,"given":"Peter D.","family":"Cole","sequence":"additional","affiliation":[{"name":"10Rutgers Cancer Institute, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghai","family":"Duan","sequence":"additional","affiliation":[{"name":"20ECOG-ACRIN Biostatistical Center, Brown University School of Public Health, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Kelly","sequence":"additional","affiliation":[{"name":"21Roswell Park Comprehensive Cancer Center, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad S.","family":"Kahl","sequence":"additional","affiliation":[{"name":"12Division of Oncology, Washington University School of Medicine, Saint Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2026043011215781000_bib1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000447080","article-title":"Lymphoma in adolescents and young adults","volume":"43","author":"Brugieres","year":"2016","journal-title":"Prog Tumor Res"},{"issue":"4","key":"2026043011215781000_bib2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"issue":"25","key":"2026043011215781000_bib3","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"2026043011215781000_bib4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bjh.16014","article-title":"Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group","volume":"187","author":"Kelly","year":"2019","journal-title":"Br J Haematol"},{"issue":"18","key":"2026043011215781000_bib5","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2206660","article-title":"Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin's lymphoma","volume":"387","author":"Castellino","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"2026043011215781000_bib6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.exphem.2005.11.008","article-title":"Epstein-Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin's lymphoma?","volume":"34","author":"Khan","year":"2006","journal-title":"Exp Hematol"},{"issue":"3","key":"2026043011215781000_bib7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/path.2711","article-title":"The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape","volume":"221","author":"Aldinucci","year":"2010","journal-title":"J Pathol"},{"issue":"14","key":"2026043011215781000_bib8","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2010.32.8401","article-title":"Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment","volume":"29","author":"Steidl","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026043011215781000_bib9","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1080\/10428190802163339","article-title":"Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: tumor and microenvironment","volume":"49","author":"Hsi","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2026043011215781000_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrc2542","article-title":"The biology of Hodgkin's lymphoma","volume":"9","author":"Kuppers","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"19","key":"2026043011215781000_bib11","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026043011215781000_bib12","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"20","key":"2026043011215781000_bib13","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.1182\/bloodadvances.2023010334","article-title":"Nivolumab for relapsed\/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study","volume":"7","author":"Ansell","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"2026043011215781000_bib14","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood.2022019386","article-title":"Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed\/refractory classical Hodgkin lymphoma","volume":"142","author":"Armand","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2026043011215781000_bib15","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2008-07-168468","article-title":"CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation","volume":"113","author":"Bashey","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2026043011215781000_bib16","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s40596-020-01243-8","article-title":"The future is knocking: how artificial intelligence will fundamentally change psychiatry","volume":"44","author":"Brunn","year":"2020","journal-title":"Acad Psychiatry"},{"issue":"27","key":"2026043011215781000_bib17","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026043011215781000_bib18","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"issue":"18","key":"2026043011215781000_bib19","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"21","key":"2026043011215781000_bib20","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"issue":"8852","key":"2026043011215781000_bib21","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"issue":"9323","key":"2026043011215781000_bib22","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"issue":"6","key":"2026043011215781000_bib23","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","article-title":"Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804","volume":"18","author":"Bartlett","year":"2007","journal-title":"Ann Oncol"},{"issue":"1","key":"2026043011215781000_bib24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3324\/haematol.10661","article-title":"Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma","volume":"92","author":"Santoro","year":"2007","journal-title":"Haematologica"},{"issue":"27","key":"2026043011215781000_bib25","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1200\/JCO.2016.66.4466","article-title":"Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: final results of a multicenter phase II study","volume":"34","author":"Santoro","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026043011215781000_bib26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/bloodadvances.2019000984","article-title":"Five-year results of the BEGEV salvage regimen in relapsed\/refractory classical Hodgkin lymphoma","volume":"4","author":"Santoro","year":"2020","journal-title":"Blood Adv"},{"issue":"25","key":"2026043011215781000_bib27","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2026043011215781000_bib28","doi-asserted-by":"crossref","first-page":"e70126","DOI":"10.1002\/hem3.70126","article-title":"Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed\/refractory Hodgkin lymphoma","volume":"9","author":"Mei","year":"2025","journal-title":"Hemasphere"},{"issue":"28","key":"2026043011215781000_bib29","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026043011215781000_bib30","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaoncol.2022.7975","article-title":"Pembrolizumab added to ifosfamide, carboplatin, and etoposide chemotherapy for relapsed or refractory classic Hodgkin lymphoma: a multi-institutional phase 2 investigator-initiated nonrandomized clinical trial","volume":"9","author":"Bryan","year":"2023","journal-title":"JAMA Oncol"},{"issue":"1","key":"2026043011215781000_bib31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.2019000215","article-title":"PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation","volume":"134","author":"Armand","year":"2019","journal-title":"Blood"},{"issue":"suppl 16","key":"2026043011215781000_bib32","first-page":"19037","article-title":"Outcomes with nivolumab maintenance after autologous hematopoietic stem cell transplantation in relapsed\/refractory Hodgkin lymphoma: a systematic review and meta-analysis","volume":"43","author":"Aijaz","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026043011215781000_bib33","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/ajh.26827","article-title":"Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed\/refractory classic Hodgkin lymphoma","volume":"98","author":"Desai","year":"2023","journal-title":"Am J Hematol"},{"issue":"10","key":"2026043011215781000_bib34","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1634\/theoncologist.2020-0167","article-title":"Checkpoint blockade treatment may sensitize Hodgkin lymphoma to subsequent therapy","volume":"25","author":"Carreau","year":"2020","journal-title":"Oncologist"},{"issue":"10","key":"2026043011215781000_bib35","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.2020007400","article-title":"Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma","volume":"137","author":"Allen","year":"2021","journal-title":"Blood"},{"issue":"15","key":"2026043011215781000_bib36","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin's lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"2026043011215781000_bib37","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3324\/haematol.2021.278311","article-title":"Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis","volume":"107","author":"Nieto","year":"2022","journal-title":"Haematologica"},{"issue":"3","key":"2026043011215781000_bib38","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jamaoncol.2024.5627","article-title":"Transplant-free approach in relapsed Hodgkin lymphoma in children, adolescents, and young adults: a nonrandomized clinical trial","volume":"11","author":"Daw","year":"2025","journal-title":"JAMA Oncol"},{"issue":"7","key":"2026043011215781000_bib39","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1158\/2767-9764.CRC-24-0252","article-title":"Tumor-immune signatures of treatment resistance to brentuximab vedotin with ipilimumab and\/or nivolumab in Hodgkin lymphoma","volume":"4","author":"Gonzalez-Kozlova","year":"2024","journal-title":"Cancer Res Commun"}],"updated-by":[{"DOI":"10.1182\/blood.2026034829","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000}}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/18\/2041\/2514868\/blood_bld-2025-029546-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/18\/2041\/2514868\/blood_bld-2025-029546-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:22:08Z","timestamp":1777562528000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/18\/2041\/566483\/A-randomized-phase-2-study-of-ipilimumab-nivolumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":39,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2026,4,30]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025029546","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,30]]},"published":{"date-parts":[[2026,4,30]]}}}